The pioneering phase I clinical trial at MD Anderson Cancer Center of cord blood derived CD19 CAR-NK cells represents the most advanced clinical data available and provides important insights for AML CAR-NK development [17]. The gene discussed is CD19; the disease is acute myeloid leukemia.